Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more
Immutep Ltd (IMM) - Total Assets
Latest total assets as of June 2025: AU$156.98 Million AUD
Based on the latest financial reports, Immutep Ltd (IMM) holds total assets worth AU$156.98 Million AUD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Immutep Ltd - Total Assets Trend (2000–2025)
This chart illustrates how Immutep Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Immutep Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Immutep Ltd's total assets of AU$156.98 Million consist of 95.0% current assets and 5.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$17.26 Million | 42.9% |
| Accounts Receivable | AU$7.46K | 0.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$569.48K | 0.4% |
| Intangible Assets | AU$7.09 Million | 4.5% |
| Goodwill | AU$109.96K | 0.1% |
Asset Composition Trend (2000–2025)
This chart illustrates how Immutep Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immutep Ltd's current assets represent 95.0% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 42.9% of total assets in 2025, up from 32.8% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is cash and equivalents at 42.9% of total assets.
Immutep Ltd Competitors by Total Assets
Key competitors of Immutep Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Immutep Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Immutep Ltd generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Immutep Ltd is currently not profitable relative to its asset base.
Immutep Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.69 | 18.25 | 9.26 |
| Quick Ratio | 11.69 | 18.25 | 9.26 |
| Cash Ratio | 1.35 | 6.38 | 4.02 |
| Working Capital | AU$136.34 Million | AU$ 180.86 Million | AU$ 27.79 Million |
Immutep Ltd - Advanced Valuation Insights
This section examines the relationship between Immutep Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.79 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -22.1% |
| Total Assets | AU$156.98 Million |
| Market Capitalization | $39.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Immutep Ltd's assets below their book value (0.25 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Immutep Ltd's assets decreased by 22.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Immutep Ltd (2000–2025)
The table below shows the annual total assets of Immutep Ltd from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$156.98 Million | -22.12% |
| 2024-06-30 | AU$201.58 Million | +36.71% |
| 2023-06-30 | AU$147.45 Million | +44.32% |
| 2022-06-30 | AU$102.17 Million | +24.55% |
| 2021-06-30 | AU$82.03 Million | +76.04% |
| 2020-06-30 | AU$46.60 Million | +14.94% |
| 2019-06-30 | AU$40.54 Million | -13.74% |
| 2018-06-30 | AU$47.00 Million | +34.42% |
| 2017-06-30 | AU$34.96 Million | -17.84% |
| 2016-06-30 | AU$42.55 Million | +37.34% |
| 2015-06-30 | AU$30.98 Million | +22.09% |
| 2014-06-30 | AU$25.38 Million | -22.66% |
| 2013-06-30 | AU$32.81 Million | -21.14% |
| 2012-06-30 | AU$41.61 Million | -27.81% |
| 2011-06-30 | AU$57.64 Million | +203.19% |
| 2010-06-30 | AU$19.01 Million | +663.62% |
| 2009-06-30 | AU$2.49 Million | -11.75% |
| 2008-06-30 | AU$2.82 Million | -35.27% |
| 2007-06-30 | AU$4.36 Million | -40.78% |
| 2006-06-30 | AU$7.36 Million | -19.40% |
| 2005-06-30 | AU$9.13 Million | +58.31% |
| 2004-06-30 | AU$5.77 Million | +45.36% |
| 2003-06-30 | AU$3.97 Million | -33.04% |
| 2002-06-30 | AU$5.93 Million | +39.63% |
| 2001-06-30 | AU$4.24 Million | +102.58% |
| 2000-06-30 | AU$2.10 Million | -- |